Tau protein and anti-tau antibodies in patients with multiple sclerosis

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 75, Issue 3, 2012, Pages 310-313

  Fialova L ^a   Bartoš, Alěs ^b,c   Svarcova J ^d   Malbohan, I ^a,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Autoantibodies; Cerebrospinal fluid; Multiple sclerosis; Tau protein

Indexed keywords

ANTIBODY; TAU ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL;

EID: 84863192978     PISSN: 12107859     EISSN: 18024041     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A 1995; 92(22): 10369-10373.
2. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985; 101(4): 1371-1378. (Pubitemid 16203754)
3. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and non-dementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 2005; 18(3): 163-173. (Pubitemid 41284967)
4. Paraskevas GP, Kapaki E, Kararizou E, Mitsonis C, Sfagos C, Vassilopoulos D. Cerebrospinal fluid tau protein is increased in neurosyphilis: a discrimination from syphilis without nervous system involvement? Sex Transm Dis 2007; 34(4): 220-223. (Pubitemid 46606746)
5. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297(3): 187-190. (Pubitemid 32011305)
6. Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003; 60(9): 1457-1461. (Pubitemid 36554806)
7. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG J Neurol 2004, 251(4): 414-420. (Pubitemid 38501298)
8. Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M et al. Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol 2002; 47(1): 45-51.
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6(3): 131-144.
10. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001; 300(2): 95-98. (Pubitemid 32162933)
11. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol; 45(1): 30-40.
12. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta neurologica Scandinavica 2007; 115(5): 325-330. (Pubitemid 46699430)
13. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000; 43(4): 228-232. (Pubitemid 30258988)
14. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis Mult Scler 2005; 11(3): 261-265. (Pubitemid 40775179)
15. Hein Nee Maier K, Kohler A, Diem R, Sattler MB, Demmer I, Lange P et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008; 436(1): 72-76
16. Guimaraes I, Cardoso Ml, Sá MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006, 12(3): 354-356.
17. Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, Medina-Acebron S, de Bustos F, Barcenilla B et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002; 106(6): 351-354. (Pubitemid 36020742)
18. Valis M, Talab R, Stourac P, Andrys C, Masopust J. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. Neuro Endocrinol Lett 2008; 29(6): 971-976.
19. Fialová L, Bartos A, Svarcová J, Malbohan I. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 2011; 6(11): e27476.
20. Benner R, van Oudenaren A, Haaijman JJ, Slingerland-Teunissen J, Wostmann BS, Hijmans W. Regulation of the "spontaneous' (background) immunoglobulin synthesis. Int Arch Allergy Appl Immunol 1981; 66(4): 404-415. (Pubitemid 12236807)
21. Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011; 57(1): 9-15.
22. MacLennan IC. Germinal centers. Annu Rev Immunol 1994; 12: 117-139. (Pubitemid 24140411)
23. Jackola DR, Liebeler CL, Lin CY, Chiu YK, Blumenthal MN, Rosenberg A Evidence that negative feedback between antibody concentration and affinity regulates humoral response consolidation to a non-infectious antigen in infants. MoI Immunol 2005; 42(1): 19-30. (Pubitemid 39360923)
24. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-911.
25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3): 227-231. (Pubitemid 13158528)
26. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-127.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452. (Pubitemid 14237132)
28. Bartos A, Fialová L, Soukupová J, Kukal J, Malbohan I, Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007; 116(2): 100-107. (Pubitemid 47174178)
29. Bartos A, Fialová L, Soukupová J, Kukal J, Malbohan I, Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007; 254(1): 20-25. (Pubitemid 46295063)
30. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006; 410(2): 90-93. (Pubitemid 44709405)
31. Mohamed HA, Mosier DR, Zou LL, Siklos L, Alexianu ME, Engelhardt JI et al. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 2002; 69(1): 110-116 (Pubitemid 34734171)
32. Bartos A, Fialova L, Svarcova J, Cechova L, Dolezil D, Malbohan IM. Serum and cerebrospinal fluid antibodies against tau protein in multiple sclerosis. Eur J Neurol 2009; 16 (Suppl 3): 251.